Indication
Gaucher Disease
4 clinical trials
3 products
Product
EliglustatClinical trial
An Open-label Study to Assess the Absorption Through the Mouth After Three Repeated 50 mg Doses of Eliglustat Solution, Separated by 2-hour Intervals, Held in the Mouth for 30 Seconds With Swishing But Without Ingestion, in Healthy SubjectsStatus: Completed, Estimated PCD: 2014-09-21
Clinical trial
A Randomized, Three-Period Crossover Study of Single and Repeated Doses for Three Different Strengths of Eliglustat in Healthy Adult, CYP2D6 Extensive and Poor MetabolizersStatus: Completed, Estimated PCD: 2018-03-26
Clinical trial
A Single Arm, Prospective, Open Label, Multicenter Study to Evaluate Efficacy and Safety of One-year Maximum Dosage in Chinese Label of Imiglucerase Treatment in Chinese Patients Who Are Diagnosed as Gaucher Disease Type ⅢStatus: Completed, Estimated PCD: 2023-10-12
Product
CerezymeClinical trial
A Prospective, Single-center, Open-arm, Single-arm Study of the Safety and Preliminary Efficacy of Single Intravenous Infusion Administration of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type IStatus: Recruiting, Estimated PCD: 2024-08-17
Product
LY-M001